Literature DB >> 18972607

Severe acneiform eruption induced by cetuximab (Erbitux).

Jung Eun Lee1, Sang Ju Lee, Hee Jung Lee, Ju Hee Lee, Kwang Hoon Lee.   

Abstract

Epidermal growth factor has an important role in the regulation of proliferation and differentiation in epidermal keratinocytes, as well as in the survival, angiogenesis and metastasis of cancer cells. Cetuximab is a chimeric monoclonal antibody selective for the epidermal growth factor receptor that induces a broad range of cellular responses that enhance tumor sensitivity to radiotherapy and chemotherapeutic agents. However, it can cause adverse events in the patient including acneiform eruption, asthenia, abdominal pain and nausea/vomiting. We report a case of severe acneiform eruption induced by cetuximab in a 56-year-old man with colorectal cancer and liver metastases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972607      PMCID: PMC2615378          DOI: 10.3349/ymj.2008.49.5.851

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  7 in total

1.  Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors.

Authors:  Arash Kimyai-Asadi; Ming H Jih
Journal:  Arch Dermatol       Date:  2002-01

2.  Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab.

Authors:  Marcello Monti; Luca L Mancini; Benvenuto Ferrari; Daoud Rahal; Armando Santoro
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

3.  Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

Authors:  W Jacot; D Bessis; E Jorda; M Ychou; M Fabbro; J-L Pujol; B Guillot
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

4.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

Authors:  S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2005-07-12       Impact factor: 32.976

5.  Cetuximab-induced acne.

Authors:  Emmanuel Molinari; Julie De Quatrebarbes; Thierry André; Sélim Aractingi
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

Review 6.  The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.

Authors:  Siegfried Segaert; Josep Tabernero; Olivier Chosidow; Thomas Dirschka; Joern Elsner; Luca Mancini; Tim Maughan; Jean-Fran Ois Morere; Armando Santoro; Alberto Sobrero; Eric Van Cutsem; Alison Layton
Journal:  J Dtsch Dermatol Ges       Date:  2005-08       Impact factor: 5.584

Review 7.  Cetuximab: in the treatment of metastatic colorectal cancer.

Authors:  Neil A Reynolds; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  7 in total
  3 in total

Review 1.  Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Authors:  Jean-Baptiste Bachet; Lucie Peuvrel; Claude Bachmeyer; Ziad Reguiai; Pierre A Gourraud; Olivier Bouché; Marc Ychou; Rene J Bensadoun; Brigitte Dreno; Thierry André
Journal:  Oncologist       Date:  2012-03-16

2.  Drug-induced acne and rose pearl: similarities.

Authors:  Rubens Pontello; Rogerio Nabor Kondo
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

Review 3.  Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.

Authors:  Jinfeng Yu; Tong Fang; Chengyu Yun; Xue Liu; Xiaoqing Cai
Journal:  Front Mol Biosci       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.